Symbols / HRMY Stock $30.76 -0.23% Harmony Biosciences Holdings, Inc.

Healthcare • Biotechnology • United States • NGM
HRMY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jeffrey M. Dayno M.D.
Exch · Country NGM · United States
Market Cap 1.78B
Enterprise Value 1.30B
Income 145.62M
Sales 899.11M
FCF (ttm) 149.73M
Book/sh 15.73
Cash/sh 11.07
Employees 293
Insider 10d —
IPO Aug 19, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 12.40
Forward P/E 5.51
PEG —
P/S 1.98
P/B 1.96
P/C —
EV/EBITDA 6.07
EV/Sales 1.45
Quick Ratio 3.45
Current Ratio 3.58
Debt/Eq 18.08
LT Debt/Eq —
EPS (ttm) 2.48
EPS next Y 5.58
EPS Growth -29.50%
Revenue Growth 16.60%
EPS Gr Q/Q -28.70%
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-07
ROA 10.18%
ROE 17.86%
ROIC —
Gross Margin 76.55%
Oper. Margin 17.31%
Profit Margin 16.20%
Shs Outstand 57.89M
Shs Float 51.73M
Insider Own 11.68%
Instit Own 96.86%
Short Float 15.96%
Short Ratio 8.11
Short Interest 6.90M
52W High 40.87
vs 52W High -24.74%
52W Low 25.52
vs 52W Low 20.53%
Beta 0.96
Impl. Vol. 1.52%
Rel Volume 0.49
Avg Volume 1.00M
Volume 493.76K
Target (mean) $44.36
Tgt Median $43.00
Tgt Low $28.00
Tgt High $85.00
# Analysts 11
Recom Buy
Prev Close $30.83
Price $30.76
Change -0.23%
About

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$44.36
Mean price target
2. Current target
$30.76
Latest analyst target
3. DCF / Fair value
$46.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.76
Low
$28.00
High
$85.00
Mean
$44.36

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 main Truist Securities Hold → Hold $29
2026-02-25 main UBS Neutral → Neutral $36
2026-02-25 reit HC Wainwright & Co. Buy → Buy $55
2026-02-25 main B of A Securities Underperform → Underperform $28
2026-02-25 main Needham Buy → Buy $44
2026-02-11 down UBS Buy → Neutral $46
2026-01-08 main Truist Securities Buy → Buy $45
2025-12-01 main Mizuho Outperform → Outperform $46
2025-11-24 reit HC Wainwright & Co. Buy → Buy $55
2025-11-24 reit Needham Buy → Buy $42
2025-11-06 main Mizuho Outperform → Outperform $39
2025-10-15 main UBS Buy → Buy $43
2025-09-25 main Mizuho Outperform → Outperform $35
2025-09-25 main Deutsche Bank Buy → Buy $36
2025-09-25 main HC Wainwright & Co. Buy → Buy $55
2025-09-24 main Needham Buy → Buy $41
2025-07-21 init Truist Securities — → Buy $48
2025-07-10 main Deutsche Bank Buy → Buy $55
2025-05-15 main Mizuho Outperform → Outperform $48
2025-05-07 reit Needham Buy → Buy $49
News
RSS: Latest HRMY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-07 ZAESKE ADAM H. Officer — 7,500 — —
2026-01-26 KAPADIA SANDIP S. Chief Financial Officer — 3,746 $37.15 $139,171
2026-01-23 DAYNO JEFFREY M Chief Executive Officer — 23,500 — —
2026-01-23 KAPADIA SANDIP S. Chief Financial Officer — 8,538 — —
2026-01-23 SERAFIN ANDREW Officer — 5,100 — —
2026-01-23 BUDUR KUMAR Officer — 4,850 — —
2026-01-15 KAPADIA SANDIP S. Chief Financial Officer — 20,961 $35.92 $752,833
2025-12-12 DAYNO JEFFREY M Chief Executive Officer — 20,000 $8.22 $164,400
2025-12-12 DAYNO JEFFREY M Chief Executive Officer — 25,933 $40.11 $1,040,103
2025-12-05 KAPADIA SANDIP S. Chief Financial Officer — 20,000 $29.03 $580,600
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
868.45
+21.51%
714.73
+22.80%
582.02
+32.93%
437.86
Operating Revenue
868.45
+21.51%
714.73
+22.80%
582.02
+32.93%
437.86
Cost Of Revenue
198.34
+26.48%
156.81
+29.35%
121.24
+45.23%
83.48
Reconciled Cost Of Revenue
198.34
+26.48%
156.81
+29.35%
121.24
+45.23%
83.48
Gross Profit
670.11
+20.11%
557.92
+21.08%
460.79
+30.03%
354.37
Operating Expense
461.64
+25.76%
367.09
+36.59%
268.76
+14.76%
234.19
Research And Development
189.59
+30.01%
145.82
+91.72%
76.06
+7.30%
70.89
Selling General And Administration
272.05
+22.95%
221.27
+14.83%
192.69
+18.00%
163.30
Selling And Marketing Expense
119.51
+7.75%
110.92
+13.87%
97.40
+22.85%
79.28
General And Administrative Expense
152.54
+38.23%
110.35
+15.81%
95.29
+13.42%
84.02
Other Gand A
152.54
+38.23%
110.35
+15.81%
95.29
+13.42%
84.02
Total Expenses
659.98
+25.97%
523.91
+34.34%
389.99
+22.77%
317.67
Operating Income
208.47
+9.25%
190.83
-0.63%
192.03
+59.78%
120.19
Total Operating Income As Reported
208.47
+9.25%
190.83
-0.63%
192.03
+59.78%
120.19
EBITDA
255.05
+9.27%
233.41
+5.37%
221.51
+50.83%
146.87
Normalized EBITDA
255.05
+9.27%
233.41
+0.92%
231.28
+57.48%
146.87
Reconciled Depreciation
25.34
+5.07%
24.11
-1.01%
24.36
+4.17%
23.39
EBIT
229.71
+9.75%
209.30
+6.16%
197.15
+59.66%
123.48
Total Unusual Items
0.00
0.00
+100.00%
-9.77
0.00
Total Unusual Items Excluding Goodwill
0.00
0.00
+100.00%
-9.77
0.00
Special Income Charges
0.00
0.00
+100.00%
-9.77
0.00
Other Special Charges
—
—
9.77
—
Net Income
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Pretax Income
215.06
+12.13%
191.80
+10.62%
173.40
+65.63%
104.69
Net Non Operating Interest Income Expense
7.28
+595.51%
1.05
+111.59%
-9.03
+42.39%
-15.67
Interest Expense Non Operating
14.65
-16.27%
17.50
-26.35%
23.76
+26.40%
18.80
Net Interest Income
7.28
+595.51%
1.05
+111.59%
-9.03
+42.39%
-15.67
Interest Expense
14.65
-16.27%
17.50
-26.35%
23.76
+26.40%
18.80
Interest Income Non Operating
21.92
+18.24%
18.54
+25.88%
14.73
+371.21%
3.13
Interest Income
21.92
+18.24%
18.54
+25.88%
14.73
+371.21%
3.13
Other Income Expense
-0.68
-900.00%
-0.07
+99.29%
-9.61
-5784.62%
0.17
Other Non Operating Income Expenses
-0.68
-900.00%
-0.07
-142.77%
0.16
-5.92%
0.17
Tax Provision
56.38
+21.74%
46.31
+3.97%
44.54
+158.01%
-76.78
Tax Rate For Calcs
0.00
+8.51%
0.00
-6.01%
0.00
+22.33%
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-2.51
0.00
Net Income Including Noncontrolling Interests
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Net Income From Continuing Operation Net Minority Interest
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Net Income From Continuing And Discontinued Operation
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Net Income Continuous Operations
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Normalized Income
158.69
+9.07%
145.49
+6.89%
136.11
-24.99%
181.47
Net Income Common Stockholders
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Diluted EPS
2.71
+7.97%
2.51
+17.84%
2.13
-28.28%
2.97
Basic EPS
2.76
+7.81%
2.56
+17.97%
2.17
-29.32%
3.07
Basic Average Shares
57.49
+1.07%
56.89
-4.35%
59.47
+0.50%
59.17
Diluted Average Shares
58.54
+1.17%
57.87
-4.15%
60.37
-1.19%
61.10
Diluted NI Availto Com Stockholders
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Line Item Trend 2023-12-31
Total Assets
811.45
Current Assets
451.07
Cash Cash Equivalents And Short Term Investments
353.46
Cash And Cash Equivalents
311.66
Other Short Term Investments
41.80
Receivables
74.14
Accounts Receivable
74.14
Inventory
5.36
Raw Materials
1.06
Work In Process
2.02
Finished Goods
2.28
Prepaid Assets
12.57
Other Current Assets
5.54
Total Non Current Assets
360.38
Net PPE
0.37
Goodwill And Other Intangible Assets
137.11
Other Intangible Assets
137.11
Investments And Advances
72.17
Non Current Deferred Assets
144.16
Non Current Deferred Taxes Assets
144.16
Other Non Current Assets
6.57
Total Liabilities Net Minority Interest
344.46
Current Liabilities
163.78
Payables And Accrued Expenses
117.22
Payables
17.73
Accounts Payable
17.73
Current Accrued Expenses
99.49
Pensionand Other Post Retirement Benefit Plans Current
23.75
Current Debt And Capital Lease Obligation
15.00
Current Debt
15.00
Other Current Borrowings
15.00
Other Current Liabilities
7.81
Total Non Current Liabilities Net Minority Interest
180.68
Long Term Debt And Capital Lease Obligation
178.57
Long Term Debt
178.57
Other Non Current Liabilities
2.11
Stockholders Equity
466.99
Common Stock Equity
466.99
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
—
Share Issued
56.77
Ordinary Shares Number
56.77
Treasury Shares Number
0.00
Additional Paid In Capital
610.27
Retained Earnings
-143.28
Gains Losses Not Affecting Retained Earnings
0.00
Other Equity Adjustments
0.00
Total Equity Gross Minority Interest
466.99
Total Capitalization
645.56
Working Capital
287.29
Invested Capital
660.56
Total Debt
193.57
Net Tangible Assets
329.88
Tangible Book Value
329.88
Available For Sale Securities
72.17
Interest Payable
3.35
Inventories Adjustments Allowances
0.00
Investmentin Financial Assets
72.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
348.20
+58.40%
219.82
+0.20%
219.39
+51.86%
144.47
Cash Flow From Continuing Operating Activities
348.20
+58.40%
219.82
+0.20%
219.39
+51.86%
144.47
Net Income From Continuing Operations
158.69
+9.07%
145.49
+12.91%
128.85
-28.99%
181.47
Depreciation Amortization Depletion
25.34
+5.07%
24.11
-1.01%
24.36
+4.17%
23.39
Depreciation
1.49
+458.05%
0.27
-48.05%
0.51
+22.67%
0.42
Amortization Cash Flow
23.84
+0.00%
23.84
+0.00%
23.84
+3.83%
22.97
Depreciation And Amortization
25.34
+5.07%
24.11
-1.01%
24.36
+4.17%
23.39
Amortization Of Intangibles
23.84
+0.00%
23.84
+0.00%
23.84
+3.83%
22.97
Other Non Cash Items
36.29
-21.95%
46.49
+701.21%
5.80
+48.00%
3.92
Stock Based Compensation
44.90
+5.38%
42.60
+34.37%
31.70
+21.14%
26.17
Deferred Tax
-7.30
+75.08%
-29.30
-118.33%
-13.42
+84.39%
-85.94
Deferred Income Tax
-7.30
+75.08%
-29.30
-118.33%
-13.42
+84.39%
-85.94
Operating Gains Losses
—
—
9.77
—
Change In Working Capital
91.82
+1354.16%
-7.32
-120.90%
35.03
+953.26%
-4.11
Change In Receivables
-13.75
-54.66%
-8.89
+54.16%
-19.40
+2.50%
-19.90
Changes In Account Receivables
-13.75
-54.66%
-8.89
+54.16%
-19.40
+2.50%
-19.90
Change In Inventory
1.84
+200.33%
-1.83
-72.14%
-1.07
-889.63%
0.14
Change In Prepaid Assets
31.79
+1156.75%
-3.01
-4164.86%
0.07
+100.98%
-7.55
Change In Payables And Accrued Expense
3.95
+173.35%
-5.38
-160.16%
8.95
+221.33%
2.79
Change In Accrued Expense
—
—
46.48
+125.96%
20.57
Change In Payable
3.95
+173.35%
-5.38
-160.16%
8.95
+221.33%
2.79
Change In Account Payable
3.95
+173.35%
-5.38
-160.16%
8.95
+221.33%
2.79
Change In Other Current Assets
—
—
—
—
Change In Other Current Liabilities
67.99
+476.27%
11.80
-74.61%
46.48
+127.62%
20.42
Investing Cash Flow
-39.65
+41.25%
-67.48
-45.32%
-46.44
+67.26%
-141.83
Cash Flow From Continuing Investing Activities
-39.65
+41.25%
-67.48
-45.32%
-46.44
+67.26%
-141.83
Net PPE Purchase And Sale
-0.31
+73.11%
-1.15
-269.55%
-0.31
-81.40%
-0.17
Purchase Of PPE
-0.31
+73.11%
-1.15
-269.55%
-0.31
-81.40%
-0.17
Capital Expenditure
-0.31
+73.11%
-1.15
-269.55%
-0.31
-81.40%
-0.17
Net Investment Purchase And Sale
-5.09
+24.74%
-6.76
+26.18%
-9.16
+90.99%
-101.66
Purchase Of Investment
-86.15
+18.18%
-105.29
+17.40%
-127.47
-15.12%
-110.73
Sale Of Investment
81.06
-17.73%
98.53
-16.72%
118.31
+1204.54%
9.07
Net Business Purchase And Sale
-19.25
+43.50%
-34.07
+7.84%
-36.97
0.00
Purchase Of Business
-19.25
+43.50%
-34.07
+7.84%
-36.97
0.00
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-40.00
Purchase Of Intangibles
—
—
0.00
+100.00%
-40.00
Net Other Investing Changes
-15.00
+41.18%
-25.50
—
-40.00
Financing Cash Flow
-9.05
+17.71%
-11.00
+89.58%
-105.55
-1642.93%
6.84
Cash Flow From Continuing Financing Activities
-9.05
+17.71%
-11.00
+89.58%
-105.55
-1642.93%
6.84
Net Issuance Payments Of Debt
-16.25
-8.33%
-15.00
-1100.00%
-1.25
+37.50%
-2.00
Issuance Of Debt
0.00
0.00
-100.00%
200.00
0.00
Repayment Of Debt
-16.25
-8.33%
-15.00
+92.55%
-201.25
-9962.50%
-2.00
Long Term Debt Issuance
0.00
0.00
-100.00%
200.00
0.00
Long Term Debt Payments
-16.25
-8.33%
-15.00
+92.55%
-201.25
-9962.50%
-2.00
Net Long Term Debt Issuance
-16.25
-8.33%
-15.00
-1100.00%
-1.25
+37.50%
-2.00
Net Common Stock Issuance
0.00
0.00
+100.00%
-100.00
0.00
Common Stock Payments
0.00
0.00
+100.00%
-100.00
0.00
Repurchase Of Capital Stock
0.00
0.00
+100.00%
-100.00
0.00
Proceeds From Stock Option Exercised
10.21
+56.98%
6.50
+28.61%
5.05
-42.82%
8.84
Net Other Financing Charges
-3.00
-20.30%
-2.50
+73.31%
-9.36
—
Changes In Cash
299.50
+111.90%
141.34
+109.72%
67.40
+611.30%
9.47
Beginning Cash Position
453.27
+45.31%
311.93
+27.56%
244.53
+4.03%
235.06
End Cash Position
752.77
+66.08%
453.27
+45.31%
311.93
+27.56%
244.53
Free Cash Flow
347.89
+59.09%
218.67
-0.19%
219.07
+51.83%
144.29
Interest Paid Supplemental Data
14.69
-15.20%
17.32
-13.64%
20.05
+22.53%
16.36
Income Tax Paid Supplemental Data
19.82
-75.11%
79.64
+65.10%
48.23
+281.44%
12.64
Amortization Of Securities
-1.52
+32.73%
-2.26
+16.72%
-2.71
-528.47%
-0.43
Common Stock Issuance
—
—
0.00
0.00
Issuance Of Capital Stock
—
—
0.00
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category